All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Multiple Myeloma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2018-01-22T15:01:22.000Z

Daratumumab granted Priority Review as a frontline regimen

Jan 22, 2018
Share:

Bookmark this article

On 19 January 2018, the US Food and Drug Administration (FDA) recommended that daratumumab be granted Priority Review as a frontline regimen in Multiple Myeloma (MM). This follows the presentation of data from the phase III ALCYONE trial at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition in 2017 as a late-breaking abstract, as well as the timely publication of the data in the New England Journal of Medicine in December 2017.

The recommendation is that daratumumab can be given in combination with bortezomib, melphalan and prednisone (abbreviated as D-VMP) to treat patients with newly diagnosed (ND) MM who are ineligible for autologous stem cell transplant (ASCT). A full decision is expected by 21 May 2018.

The ALCYONE study enrolled 706 patients and yielded highly impressive data, with a 50% reduction in the risk of progression or death with daratumumab (HR = 0.5), when combined with the SOC regimen of VMP alone.

This move towards daratumumab as a frontline regimen is exciting, as it opens up the possibility of much wider use across all stages of the disease. Indeed, given that much of the data presented at ASH 2017 indicated that ‘everything is better with daratumumab’, it is likely we will see the indications for daratumumab expand further in the coming months. This will certainly be welcome news for both Genmab and Janssen, who develop the drug together, as well as transplant ineligible patients who will now have wider options.

Newsletter

Subscribe to get the best content related to multiple myeloma delivered to your inbox